Published in AIDS Weekly, November 29th, 1999
Immtech conducted human trials with HIV patients in 1996, and it plans to expand upon human trials of its unique immune-stimulating protein in 2000 with cancer and HIV patients.
"A key issue in the large-scale production of rmCRP has been resolved, allowing Immtech to quickly and efficiently purify large amounts of the protein suitable for human clinical trials," said Dr. Lawrence A. Potempa, Immtech. "Integral to the development of any therapeutic agent is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.